Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension

Respiration

Volumn 75, Issue 3, 2008, Pages 272-280

  Ulrich, Silvia ^a,b   Nicolls, Mark R ^a   Taraseviciene, Laima ^a   Speich, Rudolf ^b   Voelkel, Norbert ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

CD25; CD4; CD8; FoxP3; Idiopathic pulmonary arterial hypertension; Regulatory T cells

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYPERTENSION, PULMONARY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; PROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY;

EID: 41349089311     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111548     Document Type: Article

References (86)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
2. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF: The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001;22:405-418.
3. Voelkel NF, Cool C: Pathology of pulmonary hypertension. Cardiol Clin 2004;22:343-351, v.
4. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, Trembath RC: Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-84.
5. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G: Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004;43:33S-39S.
6. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC: Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 2000;37:741-745.
7. Sztrymf B, Yaici A, Girerd B, Humbert M: Genes and pulmonary arterial hypertension. Respiration 2007;74:123-132.
8. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF: Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005;26:1110-1118.
9. Carreira PE: Pulmonary hypertension in autoimmune rheumatic diseases. Autoimmun Rev 2004;3:313-320.
10. Gurubhagavatula I, Palevsky HI: Pulmonary hypertension in systemic autoimmune disease. Rheum Dis Clin North Am 1997;23:365-394.
11. Kondo H: Autoimmune aspects of pulmonary hypertension in collagen vascular diseases. Intern Med 2003;42:1163-1164.
12. Magliano M, Isenberg DA, Hillson J: Pulmonary hypertension in autoimmune rheumatic diseases: where are we now? Arthritis Rheum 2002;46:1997-2009.
13. Rabinovitch M: Autoimmune disease and unexplained pulmonary hypertension. Circulation 1992;85:380-381.
14. Yanai-Landau H, Amital H, Bar-Dayan Y, Levy Y, Gur H, Lin HC, Alosachie IJ, Peter JB, Shoenfeld Y: Autoimmune aspects of primary pulmonary hypertension. Pathobiology 1995;63:71-75.
15. Tew MB, Arnett FC, Reveille JD, Tan FK: Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002;46:2829-2830.
16. Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byron MA, Pearson JD: Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988;72:450-456.
17. Negi VS, Tripathy NK, Misra R, Nityanand S: Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998;25:462-466.
18. Wusirika R, Ferri C, Marin M, Knight DA, Waldman WJ, Ross P Jr, Magro CM: The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and Western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003;120:596-606.
19. Tamby MC, Chanseaud Y, Humbert M, Fermanian J, Guilpain P, Garcia-de-la-Pena-Lefebvre P, Brunet S, Servettaz A, Weill B, Simonneau G, Guillevin L, Boissier MC, Mouthon L: Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005;60:765-772.
20. Tamby MC, Humbert M, Guilpain P, Servettaz A, Dupin N, Christner JJ, Simonneau G, Fermanian J, Weill B, Guillevin L, Mouthon L: Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006;28:799-807.
21. Tuder RM, Groves B, Badesch DB, Voelkel NF: Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285.
22. Tuder RM, Voelkel NF: Angiogenesis and pulmonary hypertension: a unique process in a unique disease. Antioxid Redox Signal 2002;4:833-843.
23. Voelkel NF, Tuder RM: Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995;8:2129-2138.
24. Dorfmuller P, Perros F, Balabanian K, Humbert M: Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-363.
25. Tsunemi S, Iwasaki T, Imado T, Higasa S, Kakishita E, Shirasaka T, Sano H: Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS 2005;19:879-886.
26. Taraseviciene-Stewart L, Scerbavicius DK, Burns N, Cool CD, Nicolls MR, Voelkel NF: The protective role of T-lymphocytes in pulmonary vascular remodeling. Chest 2005;128:571S-572S.
27. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF: Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007;175:1280-1289.
28. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM: Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438.
29. Burnet F: The Clonal Selection Theory of Acquired Immunity. Cambridge, Cambridge University Press, 1959.
30. Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
31. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
32. Shevach EM: Certified professionals: CD4 (+)CD25(+)suppressor T cells. J Exp Med 2001;193:F41-F46.
33. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
34. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
35. Kasprowicz DJ, Droin N, Soper DM, Ramsdell F, Green DR, Ziegler SF: Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death. Eur J Immunol 2005;35:3424-3432.
36. Sakaguchi S, Sakaguchi N: Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005;24:211-226.
37. Sakaguchi S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562.
38. Sakaguchi S, Takahashi T, Yamazaki S, Kuniyasu Y, Itoh M, Sakaguchi N, Shimizu J: Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect 2001;3:911-918.
39. Boyer O, Saadoun D, Abriol J, Dodille M, Piette JC, Cacoub P, Klatzmann D: CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004;103:3428-3430.
40. Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-276.
41. Terabe M, Berzofsky JA: Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 2004;16:157-162.
42. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-612.
43. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-1177.
44. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, Sato Y, Abo T, Horwitz DA, Aoyagi Y: Increase of CD4(+) CD25(+) regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006;45:178-181.
45. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-2464.
46. Danese S, Rutella S: The Janus face of CD4+CD25+ regulatory T cells in cancer and autoimmunity. Curr Med Chem 2007;14:649-666.
47. Liu MF, Wang CR, Fung LL, Wu CR: Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004;59:198-202.
48. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T: Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum 2000;43:617-627.
49. Jonuleit H, Schmitt E: The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003;171:6323-6327.
50. Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A: Modulation of the CD8+ T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005;79:3322-3328.
51. Walsh PT, Benoit BM, Wysocka M, Dalton NM, Turka LA, Rook AH: A role for regulatory T cells in cutaneous T-cell lymphoma; induction of a CD4+ CD25+ Foxp3+ T-cell phenotype associated with HTLV-1 infection. J Invest Dermatol 2006;126:690-692.
52. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
53. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003;112:1437-1443.
54. Sakaguchi S: Immunologic tolerance maintained by regulatory T cells: implications for autoimmunity, tumor immunity and transplantation tolerance. Vox Sang 2002;83(suppl 1):151-153.
55. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM: Primary pulmonary hypertension between inflammation and cancer. Chest 1998;114:225S-230S.
56. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
57. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T: Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64.
58. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Luthy R: HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-995.
59. Speich R, Jenni R, Opravil M, Pfab M, Russi EW: Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-1271.
60. Marecki J, Cool C, Voelkel N, Luciw P, Flores S: Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus. Chest 2005;128:621S-622S.
61. Bendayan D, Sarid R, Cohen A, Shitrit D, Shechtman I, Kramer MR: Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension. Respiration 2008;75:155-157.
62. Cool CD, Rai PR, Yeager ME, Hernandez-Saavedra D, Serls AE, Bull TM, Geraci MW, Brown KK, Routes JM, Tuder RM, Voelkel NF: Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003;349:1113-1122.
63. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
64. Wherry EJ, Blattman JN, Ahmed R: Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 2005;79:8960-8968.
65. Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111:837-851.
66. Klenerman P, Hill A: T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005;6:873-879.
67. Heath D, Yacoub M: Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991;44:1003-1006.
68. Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Mussot S, Mazmanian M, Herve P, Emilie D, Simonneau G, Humbert M: Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007;29:462-468.
69. Jonuleit H, Schmitt E, Steinbrink K, Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394-400.
70. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-4780.
71. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4 (+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-1222.
72. Mahnke K, Johnson TS, Ring S, Enk AH: Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 2007;46:159-167.
73. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004;172:4676-4680.
74. Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA, Tischler MD: Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-1519.
75. Fagan KA, Badesch DB: Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002;45:225-234.
76. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black CM: Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-459.
77. Sacks DG, Okano Y, Steen VD, Curtiss E, Shapiro LS, Medsger TA Jr: Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996;23:639-642.
78. Salerni R, Rodnan GP, Leon DF, Shaver JA: Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-399.
79. Thomas D, Zaccone P, Cooke A: The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy. Rev Diabet Stud 2005;2:9-18.
80. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A: Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults - a monocentric German study. Clin Immunol 2005;116:192-197.
81. Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD: Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-γ expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab 2006;290:E856-E863.
82. Suarez A, Lopez P, Gomez J, Gutierrez C: Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006;65:1512-1517.
83. Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ: Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56S-61S.
84. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ: Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62S-67S.
85. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
86. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P: Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008;75:346-349.